412 Views

Plenary

Session: Plenary Session 4: Future Innovation and Outlook for the Field of Pharmacoepidemiology

Future Innovation and Outlook for the Field of Pharmacoepidemiology

Tuesday, April 25, 2023

11:15 AM – 1:00 PM GMT

Moderator(s)

Andrew Bate

VP & Head, Safety Innovation & Analytics, Global Safety
GlaxoSmithKline, United States
Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP

VP Epidemiology
Research Triangle Institute
Barcelona, Spain

Speaker(s)

Alison Cave, PhD

Chief Safety Officer
Medicines and Healthcare products Regulatory Agency (UK)
London, United Kingdom
Robert W. Platt, PhD (he/him/his)

Professor
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
Montreal, QC, Canada
Jamie Geier (she/her/hers)

Global Head, Quantitative Safety & Epidemiology
Novartis Pharma AG
East Hanover, NJ, United States

Disclosure(s):

Susana Perez-Gutthann, MD, PhD, MPH, FISPE, FRCP: No relevant disclosure to display

Alison Cave, PhD: No financial relationships to disclose

Robert W. Platt, PhD: No relevant disclosure to display

Jamie Geier: No relevant disclosure to display

The pandemic has and is acting as a stimulus for innovation right across the field of pharmacoepidemiology. In what areas are we seeing most impetus? A range of different stakeholders will share their perspective on the changes that are and need to occur as Pharmacoepidemiology advances.

11:15-11:45: The regulatory perspective
Alison Cave, Chief Safety Officer, MHRA, United Kingdom

11:45-12:15: The academic perspective
Robert Platt, Professor, McGill University, Canada

12:15-12:45: The industry perspective
Jamie Geier, Global Head, Quantitative Safety & Epidemiology, Novartis

12:45-13:00: Discussion